Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Phase 1b Study of the Safety and Tolerability of Veliparib in Combination With Capecitabine and Radiation in Subjects With Locally Advanced Rectal Cancer (LARC)

NCT01589419 is registered in ClinicalTrials.gov with AbbVie (prior sponsor, Abbott) as lead sponsor.

NCT NCT01589419
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01589419 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Phase 1b Study of the Safety and Tolerability of Veliparib in Combination With Capecitabine and Radiation in Subjects With Locally Advanced Rectal Cancer (LARC)
Lead sponsor
AbbVie (prior sponsor, Abbott)
Phase
Phase 1
Overall status
Completed
Start date
June 30, 2012
Completion date
January 31, 2015
Enrollment
32 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced rectal cancer